SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BDR who wrote (295)7/28/1997 9:10:00 PM
From: Biomaven   of 10280
 
I haven't heard anything since the 10-K, which had this to say:

(S)-OXYBUTYNIN, the single-isomer form of the leading treatment for urinary incontinence, racemic oxybutynin (marketed by HMRI as DitropanR), is now in Phase I trials. Sepracor believes that drug therapy is not used extensively in the incontinence treatment market largely because pharmaceutical treatments, including racemic oybutynin, can cause side effects such as dry mouth, nausea, restlessness and cardiovascular effects. While substantial additional preclinical and clinical work is needed to determine the safety and efficacy profile of this drug, Sepracor believes, based on preclinical studies, that S-oxybutynin may provide a more effective treatment for urinary incontinence with reduced side effects. In July 1996, the Company received a U.S. patent for the use of (S)-oxybutynin.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News